Matches in SemOpenAlex for { <https://semopenalex.org/work/W44607965> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W44607965 endingPage "4553" @default.
- W44607965 startingPage "4553" @default.
- W44607965 abstract "4553 Purpose: We evaluated whether the time to return to the baseline prostate-specific antigen level (PSA response duration) was significantly associated with time to death following randomization for men with hormone refractory metastatic prostate cancer (HRMPC). Patients and Methods: The study (N = 213) and validation (N = 281) cohorts comprised 494 men with HRMPC treated on 4 prospective randomized phase II studies between 2/96 and 10/01. Cox regression was used to evaluate whether a significant association existed between the PSA response duration and the time to death following randomization controlling for treatment and known prognostic factors. For illustrative purposes, Kaplan Meier estimates of survival dichotomized about the median value of the PSA response duration from the study cohort were compared using a 2-sided log rank test for all men in the validation cohort whose PSA declined, and those with a PSA decline that was less than or at least 50%. Results: An increasing PSA response duration was significantly associated with a longer survival following randomization in the study (p = 0.001) and validation (p = 0.02) cohorts controlling for treatment and known prognostic factors as shown in the Table. The adjusted hazard ratio (AHR) for death was 1.9 [95% Confidence Interval (CI): 1.4, 2.6; p = 0.0002] for men in the study cohort with a PSA response duration that was less than the median value of 3 months as compared to 3 months or more. This AHR was 2.1 [95% CI: 1.2, 3.5; p = 0.01] for men in the validation cohort. Survival was significantly shorter for men in the validation cohort whose PSA response duration was less than as compared to at least the median value from the study cohort whether they experienced at least a 50% reduction (p = 0.05) in PSA or not (p = 0.03). Conclusion: The duration of the PSA response to treatment is significantly associated with the length of survival for men with HRMPC. No significant financial relationships to disclose." @default.
- W44607965 created "2016-06-24" @default.
- W44607965 creator A5001321994 @default.
- W44607965 creator A5010557443 @default.
- W44607965 creator A5027334479 @default.
- W44607965 creator A5072365761 @default.
- W44607965 creator A5089748805 @default.
- W44607965 date "2005-06-01" @default.
- W44607965 modified "2023-10-15" @default.
- W44607965 title "Intermediate end point for survival for patients with hormone refractory metastatic prostate cancer" @default.
- W44607965 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.4553" @default.
- W44607965 hasPublicationYear "2005" @default.
- W44607965 type Work @default.
- W44607965 sameAs 44607965 @default.
- W44607965 citedByCount "2" @default.
- W44607965 crossrefType "journal-article" @default.
- W44607965 hasAuthorship W44607965A5001321994 @default.
- W44607965 hasAuthorship W44607965A5010557443 @default.
- W44607965 hasAuthorship W44607965A5027334479 @default.
- W44607965 hasAuthorship W44607965A5072365761 @default.
- W44607965 hasAuthorship W44607965A5089748805 @default.
- W44607965 hasConcept C121608353 @default.
- W44607965 hasConcept C126322002 @default.
- W44607965 hasConcept C126894567 @default.
- W44607965 hasConcept C143998085 @default.
- W44607965 hasConcept C168563851 @default.
- W44607965 hasConcept C188816634 @default.
- W44607965 hasConcept C203092338 @default.
- W44607965 hasConcept C204243189 @default.
- W44607965 hasConcept C207103383 @default.
- W44607965 hasConcept C2780192828 @default.
- W44607965 hasConcept C2781406297 @default.
- W44607965 hasConcept C44249647 @default.
- W44607965 hasConcept C50382708 @default.
- W44607965 hasConcept C66339696 @default.
- W44607965 hasConcept C71924100 @default.
- W44607965 hasConcept C72563966 @default.
- W44607965 hasConceptScore W44607965C121608353 @default.
- W44607965 hasConceptScore W44607965C126322002 @default.
- W44607965 hasConceptScore W44607965C126894567 @default.
- W44607965 hasConceptScore W44607965C143998085 @default.
- W44607965 hasConceptScore W44607965C168563851 @default.
- W44607965 hasConceptScore W44607965C188816634 @default.
- W44607965 hasConceptScore W44607965C203092338 @default.
- W44607965 hasConceptScore W44607965C204243189 @default.
- W44607965 hasConceptScore W44607965C207103383 @default.
- W44607965 hasConceptScore W44607965C2780192828 @default.
- W44607965 hasConceptScore W44607965C2781406297 @default.
- W44607965 hasConceptScore W44607965C44249647 @default.
- W44607965 hasConceptScore W44607965C50382708 @default.
- W44607965 hasConceptScore W44607965C66339696 @default.
- W44607965 hasConceptScore W44607965C71924100 @default.
- W44607965 hasConceptScore W44607965C72563966 @default.
- W44607965 hasIssue "16_suppl" @default.
- W44607965 hasLocation W446079651 @default.
- W44607965 hasOpenAccess W44607965 @default.
- W44607965 hasPrimaryLocation W446079651 @default.
- W44607965 hasRelatedWork W2008604597 @default.
- W44607965 hasRelatedWork W2120739015 @default.
- W44607965 hasRelatedWork W2133235702 @default.
- W44607965 hasRelatedWork W2312983093 @default.
- W44607965 hasRelatedWork W2343768426 @default.
- W44607965 hasRelatedWork W2791790237 @default.
- W44607965 hasRelatedWork W2808552915 @default.
- W44607965 hasRelatedWork W2809220925 @default.
- W44607965 hasRelatedWork W2889106228 @default.
- W44607965 hasRelatedWork W4307224099 @default.
- W44607965 hasVolume "23" @default.
- W44607965 isParatext "false" @default.
- W44607965 isRetracted "false" @default.
- W44607965 magId "44607965" @default.
- W44607965 workType "article" @default.